

# JNJ-38877605

Catalog No: tcsc0031



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

943540-75-8

**Formula:**

$C_{19}H_{13}F_2N_7$

**Pathway:**

Protein Tyrosine Kinase/RTK

**Target:**

c-Met/HGFR

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 30$  mg/mL (79.50 mM)

**Observed Molecular Weight:**

377.35

## Product Description

JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC<sub>50</sub> of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and


serine-threonine kinases.

IC50 value: 4 nM [1]

Target: c-Met

in vitro: JNJ-38877605 shows more than 600-fold selectivity for c-Met compared with more than 200 other diverse tyrosine and serine-threonine kinases and also potently inhibits HGF-stimulated and constitutively activated c-Met phosphorylation in vitro. [1] In EBC1, GTL16, NCI-H1993, and MKN45 cells, JNJ-38877605 (500 nM) leads to a significant reduction of phosphorylation of Met and RON, another key player in invasive growth [2]. A recent study shows that JNJ-38877605 is involved in modulating secretion of IL-8, GRO $\alpha$ , uPAR and IL-6 in GTL16 cells [3].

in vivo: In mice bearing established GTL16 xenografts, JNJ-38877605, dosed orally with 40 mg/kg/day for 72 hours, results in a statistically significant decrease in the plasma levels of human IL-8 (from 0.150 ng/mL to 0.050 ng/mL) and GRO $\alpha$  (from 0.080 ng/mL to 0.030 ng/mL). While concentrations of uPAR in the blood become reduced to more than 50% at the same dose [3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!